Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). It also has anxiolytic effects.
## Primary Indications
* Adjunctive therapy for seizures in patients with Lennox-Gastaut Syndrome (LGS).
## Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every 3 to 7 days, as tolerated, up to a maximum of 20 mg twice daily.
* **Maintenance:** Doses are typically 10 mg to 20 mg twice daily.
## Pediatric Dosing
* **LGS (2 years and older):**
* **Weight-based dosing:** 0.5 mg/kg/day divided into two doses.
* **Titration:** Increase dose by 0.5 mg/kg/day every 3 to 7 days, as tolerated, up to a maximum of 1 mg/kg/day divided into two doses, not to exceed the adult maximum.
* **Maximum daily dose:** 20 mg twice daily (40 mg/day total).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be appropriate due to potential for increased exposure.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic or renal impairment (relative contraindication, use with caution).
## Adverse Effects
Common: Somnolence, decreased appetite, constipation, drooling, fatigue, aggression, vomiting, gait disturbance, mood-related changes, upper respiratory tract infection.
Serious: **Respiratory depression**, **sedation**, **dependence and withdrawal**, suicidal behavior or ideation, severe skin reactions (e.g., Stevens-Johnson syndrome), paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes. Monitor closely.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations and efficacy.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CNS Stimulants:** May decrease the efficacy of clobazam.
## Monitoring
* Monitor for excessive sedation, respiratory depression, and signs of dependence or withdrawal, especially upon initiation or dose changes.
* Monitor for suicidal behavior or ideation.
* Assess seizure frequency and severity.
* Consider therapeutic drug monitoring (TDM) for clobazam and its active metabolite, N-desmethylclobazam (norclobazam), particularly in cases of suspected non-adherence, toxicity, or lack of efficacy. Reference ranges are not well-established and vary by laboratory.
## Clinical Pearls
* Clobazam's efficacy in LGS is thought to be related to its action on T-type calcium channels, in addition to GABAergic effects.
* Withdrawal symptoms can occur upon abrupt discontinuation, so gradual tapering is recommended.
* The active metabolite, N-desmethylclobazam, has a longer half-life than clobazam itself, contributing to sustained effects.
* Due to potential for dose-dependent side effects, starting at a low dose and titrating slowly is crucial.
***
*This information is intended for healthcare professionals. Please consult the official prescribing information and relevant clinical guidelines for complete details. Verify current prescribing information before making clinical decisions.*
